Tirzepatide, the active component in Mounjaro In Dubai, was employed in the Phase 3 SURMOUNT-1 weight loss clinical trials that lasted for 72 weeks. Average weight loss after using tripeptide ranged from 15% at the 5mg dose to 19.5% at the 10mg dose, 20.9% at the 15mg dose, and 3.1% with the placebo. Patients with diabetes were not eligible to participate in the experiment.